Want to see ACAD full AI Analyst Report?
ACAD Stock Chart & Stats
$22.17
-$0.09(-0.52%)
At close: 4:00 PM EST
$22.17
-$0.09(-0.52%)
Day’s Range― - ―
52-Week Range$19.69 - $28.35
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.61M
Market Cap
$4.30B
Enterprise Value$3.04K
Total Cash (Recent Filing)$851.46M
Total Debt (Recent Filing)$50.79M
Price to Earnings (P/E)11.3
Beta1.06
Next Earnings
Aug 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume1,501,823
30 Day Avg. Volume1,610,546
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$32.21Price Target Upside45.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.39
Revenue Forecast (FY)$1.24B
Bulls Say, Bears Say
Bulls Say
Low Leverage & Stronger Equity BaseACADIA’s materially improved balance sheet — very low debt-to-equity and expanded equity since 2023 — provides durable financial resilience. This conservatism supports continued commercial investment and clinical programs, lowers refinancing risk, and cushions the company against regulatory or market setbacks over months.
Improved Cash Generation And Large Cash CushionA sizable cash balance (~$851M) and materially improved operating/free cash flow in the trailing period enhance ACADIA’s ability to fund commercial expansion and near-term pivotal readouts without urgent external financing. That cash runway supports execution of multiyear growth plans and risk mitigation for development timelines.
Commercial Momentum And Product ExpansionSustained double-digit DAYBUE growth, early traction for the DAYBUE STIX formulation, rising NUPLAZID demand and a ~30% sales force expansion point to durable commercial scale-up. Expanding distribution and field coverage support longer-term revenue growth and higher adoption across physician networks and centers of excellence.
Bears Say
High Gross‑to‑net Revenue DeductionsPersistent high gross-to-net discounts erode realized product revenue and compress margins even if list volumes rise. Structural payer mix, rebates and chargebacks at these levels require higher volume growth to sustain net revenue targets and make top-line forecasts more sensitive to changes in reimbursement dynamics.
Significant SG&A Step-upA sustained ~35% increase in SG&A to fund sales force and commercialization raises the breakeven for new product uptake. If commercial momentum slows or gross-to-net pressure persists, higher fixed selling costs could compress operating margins and require sustained execution to justify the recurring expense base.
Regulatory Uncertainty For Trofinetide (Europe)Ongoing European reexamination creates a durable uncertainty over ex-US commercialization and expected peak sales for trofinetide. Delays or negative regulatory outcomes can materially reduce international opportunity, alter global launch sequencing, and force strategic pivots that affect medium-term revenue and resource allocation.
ACADIA Pharmaceuticals News
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $19.69 and its highest was $28.35 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $4.30B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 13 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on May 06, 2026. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.051 by -$0.031.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.06.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.02 in its last earnings report, missing expectations of $0.051. Following the earnings report the stock price went up 5.028%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.21 (45.31% Upside)
$32.21 (45.31% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 784.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.21%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
ACAD Stock 12 Month Forecast
Average Price Target
$32.21
▲(45.31% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―
Ownership Overview
23.27% Insiders
16.14% Mutual Funds
0.19% Other Institutional Investors
37.07% Public Companies and
Individual Investors